Floatz logo

Ipilimumab

Mesothelioma Peritoneum

TCR2 Therapeuticsmonoclonal_antibodyPhase 2Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

18 Active assets in the Mesothelioma Peritoneum cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 2BB
MITOMYCIN C
National Cancer Institute (NCI)
Phase 2B
Sodium Thiosulfate
National Cancer Institute (NCI)
Phase 2B
FLUOROURACILUM
Hospices Civils de Lyon
Phase 2B
Eloxatin
Hospices Civils de Lyon
Phase 2B

View all 20 →

Same molecule, other indications

Ipilimumab is also rated in:

metastatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Clinical Stage IV Cutaneous Melanoma AJCC v8Dormant
BB
Indicative ·
69 / 100
View asset →
cutaneous melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →